Sanguine
Sanguine provides biospecimen collection services to support medical research, specializing in precision translational medicine and cell & gene therapy development, with a focus on patient convenience and high retention rates.
Services
Sanguine offers biospecimen collection services designed to accelerate precision translational medicine and cell & gene therapy development. The company provides at-home studies and apheresis services, making it convenient for patients to participate in medical research. Key services include minimally invasive biospecimen collection, longitudinal sampling, and employer onsite collections. These services support research in autoimmune and inflammatory diseases, genetic disorders, neurodegenerative and neuropsychological conditions, hematologic, oncology, metabolic, infectious diseases, and cardiovascular areas.
Mobile Biospecimen Collection
In addition to at-home services, Sanguine operates mobile biospecimen collection services. These mobile units enable minimally invasive collection, longitudinal sampling, and onsite collections at employer locations. This approach ensures broader and more flexible participation in medical research, facilitating complex and longitudinal studies with high patient retention rates.
Biorepository
Sanguine maintains a biorepository designed for comprehensive biospecimen processing, testing, and analysis. The biorepository also offers sample storage solutions, ensuring the integrity and viability of collected biospecimens over time. This infrastructure supports detailed and rigorous research across several medical fields, ensuring the availability of high-quality, annotated biospecimens from specific patient and healthy donor populations.
Patient-Centric Approach
With a commitment to patient-centric research, Sanguine prioritizes the convenience and engagement of its over 70,000 community members. The company's services are structured to enhance patient retention, particularly for studies that require longitudinal sampling. Utilizing electronic informed consent processes that are 21 CFR part 11 compliant and HIPAA-compliant systems, Sanguine ensures that study protocols and participant information are thoroughly reviewed and approved by internationally-recognized Institutional Review Boards (IRBs).